香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Ganglong China Property Group Limited 港龍中國地產集團有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：6968） 承 董事會命 港龍中國地產集團有限公司 主 席 兼執行董事 呂 明 截 至 202 5年6月30日止六 個 月 業 績 預 告 本 公 告由港龍中國地產集團有限公 司（「本 公司」，連 同 其 附 屬 公 司，統 稱「本 集 團」）依據香港聯合交易所有限公司證券上市規 則（「上 市規則」）第13.09條及香港 法 例 第571章《證券及期貨條 例》第XIVA部項下的內幕消息 條 文（定義見上市規 則）作 出。 本 公 司董事會（「董事會」 ） 謹 此 知 會 本 公 司 股 東及有意投資者，根據就本 集 團 截至2025年6月30日止六個月之未經審核綜合管理賬 ...

Core Viewpoint - The company, Hong Kong Dragon China Properties (06968.HK), announced a total contract sales amount of approximately RMB 3.1508 billion from January to July 2025, including contributions from joint ventures and associates [1] Group 1 - The total contract sales amount achieved by the company and its joint ventures and associates is approximately RMB 3.1508 billion [1]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Core Viewpoint - The company reported a contract sales amount of approximately RMB 3.151 billion from January to July 2025, reflecting a year-on-year decrease of 0.22% [1] Group 1 - The total contract sales amount achieved by the company and its subsidiaries, along with joint ventures and associates, was approximately RMB 3.151 billion [1] - The year-on-year change in contract sales indicates a slight decline of 0.22% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 港龍中國地產集團有限公司 港龍中國地產集團有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：6968） 2025 年7月份之未經審核營運數據 港 龍中國地產集團有限公 司（「本 公 司」）董 事 會（「董 事 會」）公 佈，本公司及其附 屬 公 司（「本 集 團」），連 同 其 合 營公司和聯營公司 由2025年1月 至7月 共 實現合同 銷 售 金額約人民 幣3,150.8百 萬 元。 上 述已披露初步數據取自本集團及其合營公司和聯營公司之管理層資 料，或 會 變更並可能與本集團按年度或半年度刊發的經審核或未經審核綜合財務報 表 所呈現的數字存在差 異。這些資料不應被視為本集團現時或將來的經營或 財 務 表現的指標或測量依 據。據 此，本公告披露之資料僅供參閱而不作其他目 的。股東和潛在投資者在買賣本公司證券 ...

Core Viewpoint - The stock code 06968.HK reflects the company's industry positioning, indicating a focus on technology innovation and new economic sectors, particularly in financial technology and digital services [1][3][5]. Industry Characteristics - The "69" in the stock code may signify a connection to financial, technology, or emerging industries, with a strong inclination towards technology-driven sectors such as cloud computing, big data, and artificial intelligence [3][5]. - The final digit "8" symbolizes prosperity and good fortune in Hong Kong's market, suggesting the company's aspiration for sustained growth and a positive market image [3][5]. Business Operations - The main business areas of 06968.HK include fintech, smart payment terminals, blockchain applications, and innovative financial services, positioning the company within a rapidly evolving and technology-driven industry [5][6]. - The company is actively exploring the integration of blockchain with financial services, indicating a shift from traditional finance to fintech and intelligent payment solutions [5][6]. Industry Trends and Investment Opportunities - The global development of fintech is a significant driving force for the industry, with new payment methods and blockchain applications becoming increasingly integrated into consumers' daily lives [6][8]. - Emerging technologies present substantial opportunities for companies like 06968.HK, which is expected to achieve rapid growth through technological innovation and market expansion, especially with the rise of digital currency and cross-border payments [6][8]. Competitive Advantages - The industry has vast growth potential, with the core competitiveness of companies increasingly tied to their innovation capabilities [8]. - The company's increasing investment in research and development is expected to pave new paths in the market and enhance its resilience against risks [8]. - The growing acceptance of technology in finance and supportive policies create a favorable external environment for the company [8]. Future Strategies - Potential investment directions include expanding blockchain technology applications, entering overseas markets, and collaborating with domestic and international financial institutions [8][10]. - The company's improving financial structure, stable revenue growth, and diversified income sources provide confidence for investors [10].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Ganglong China Property Group Limited 港龍中國地產集團有限公司 呂 明 本 公 司 謹 此 就 該 公 告 補 充 以 下 額 外 資 料： (i) 誠如本公司日期為2025年6月23日 的 公 告 所 披 露，本 公 司 收 到2025年11月 票 據 主 要 票 據 持 有 人 發 出 的 加 速 還 款 通 知，基 於 未 支 付 中 期 利 息 之 故，宣 佈 該 票 據 本 金 及 應 付 未 付 利 息 立 即 到 期 應 付。本 集 團 已 與2025年11月票據的 主要票據持有人及其他三名票據持有人（合 共 持 有 該 票 據 未 償 還 本 金 總 額 超 過98%）進 行 溝 通，並 將 繼 續 與 彼 等 進 行 溝 通，以 尋 求 相 關 債 務 的 整 體 解 決 方 案，以 維 護 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 港龍中國地產集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06968 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法 ...

Core Viewpoint - The article highlights the significant rise in the stock price of Innovent Biologics, driven by a strategic partnership with GSK, which is expected to enhance the company's revenue and profit potential through licensing agreements and milestone payments [1][2]. Group 1: Company Overview - Innovent Biologics' stock reached a new high of 62.04 CNY per share, with a total market capitalization of 414.5 billion CNY following the announcement of a partnership with GSK [1]. - The partnership involves a $500 million upfront payment from GSK for exclusive global rights to the HRS-9821 project and up to 11 additional projects outside of China [1][2]. - If all milestones are achieved, the potential total payments could reach approximately $12 billion, along with sales royalties [1][2]. Group 2: Product Details - HRS-9821 is a potential best-in-class PDE3/4 inhibitor currently in Phase I clinical development for treating Chronic Obstructive Pulmonary Disease (COPD) [2]. - The product is designed to provide both bronchodilation and anti-inflammatory effects, serving as a maintenance therapy without considering previous treatment regimens [2]. - The only similar product, Ensifentrine, is projected to generate sales of approximately $42 million in 2024 and over $71.3 million in Q1 2025 [2]. Group 3: Financial Performance - Innovent Biologics reported a revenue increase of 22.63% year-on-year to 27.985 billion CNY for 2024, with a net profit of 6.337 billion CNY, marking a 47.28% increase [4]. - The financial growth is attributed to licensing agreements, including a €160 million payment from Merck Healthcare and a $100 million payment from Kailera Therapeutics [4]. - The domestic innovative drug sector has seen a surge in overseas business development (BD) transactions, with over 50 global cooperation agreements totaling more than $48.4 billion in the first half of 2025 [4].

Group 1 - The company, Longfor China, announced it is unable to pay the interest on its $180 million notes due in November 2025, signaling a potential debt default [1][3] - As of December 31, 2024, Longfor China has approximately 1.93 billion RMB in interest-bearing bank and other borrowings that are overdue, triggering a default event on the November 2025 notes [1][3] - The company has a 30-day grace period to pay the $858,000 interest that was due on May 18, 2025, but is facing liquidity pressures [1][3] Group 2 - Longfor China reported a contract sales amount of approximately 5.409 billion RMB in 2024, with 2.25 billion RMB in the first five months of the current year [5] - The company's total revenue for 2024 was 8.265 billion RMB, representing a year-on-year decline of 53.06%, and it recorded a net loss of 658 million RMB compared to a profit of 148 million RMB in the same period last year [5][6] Group 3 - Longfor China is headquartered in Shanghai and holds a national first-class real estate development qualification, having been listed on the Hong Kong Stock Exchange since July 2020 [3] - The company has strategically focused on cities in the Yangtze River Delta region, including Shanghai, Hangzhou, Suzhou, Nanjing, and Hefei, as well as the Guangdong-Hong Kong-Macau Greater Bay Area and the Chengdu-Chongqing region [3]